ArticleNeuropsychiatric disease and treatment2026
Plasma Plasminogen Activator Inhibitor-1 as a Biomarker for Disease Activity and Pharmaco-Response Prediction in Pediatric Epilepsy: A Prospective Cohort Study.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the clinical relevance of plasma plasminogen activator inhibitor-1 (PAI-1) in pediatric epilepsy, focusing on its associations with seizure severities and therapeutic outcomes. Methods: We conducted a prospective cohort study to compare the plasma PAI-1 levels quantified by ELISA across children with active epilepsy, seizure-free patients, and healthy controls. Furthermore, subgroup analyses were conducted to assess the impact of AED treatment or long-term drug response to the plasma PAI-1 levels. Results: PAI-1 levels were 2.1-fold higher in the seizure group than in the control group ( Conclusion: Our findings establish plasma PAI-1 as a promising biomarker for identifying children at high risk for pharmaco-resistant epilepsy, thereby addressing a high-burden condition. The persistence of PAI-1 elevation hints at underlying inflammatory or synaptic pathologies that may be novel therapeutic targets beyond conventional AEDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.